Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination

被引：0
|
作者：
Urbanska, E. M. [1 ]
Melchior, L. C. [1 ]
Sorensen, J. B. [1 ,2 ]
Santoni-Rugiu, E. [1 ,2 ]
机构：
[1] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
de novo MET-amplification; intrinsic ALK-TKI resistance; TKIs combination;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.12
引用
收藏
页码：S645 / S646
页数：2
相关论文
共 50 条
  • [1] ALK-tyrosine kinase inhibitor intrinsic resistance due to de novoMET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report
    Urbanska, Edyta M.
    Grauslund, Morten
    Berger, Siv M. S.
    Costa, Junia C.
    Koffeldt, Peter R.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (09) : 2453 - 2462
  • [2] Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC
    Hashimoto, Hiroshi
    Komori, Kazuyuki
    Kameda, Koji
    Taguchi, Shinichi
    Ozeki, Yuichi
    SURGICAL CASE REPORTS, 2022, 8 (01)
  • [3] An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: a case report
    Li, Hui
    Liu, Jingjing
    Lan, Shaowei
    Zhong, Rui
    Cui, Yanan
    Christopoulos, Petros
    Schenk, Erin L.
    Sasaki, Takaaki
    Cheng, Ying
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2538 - 2549
  • [4] Advanced ALK plus NSCLC New Follow-up Data on 3rd Generation ALK-TKI
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06)
  • [5] Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK plus NSCLC
    Kumar, Pragya
    Turati, Virginia
    Marusyk, Andriy
    CANCER RESEARCH, 2022, 82 (10)
  • [6] Proteasome inhibitor overcomes ALK-TKI resistance by p53 inactivation through Noxa expression in ALK rearranged NSCLC
    Tanimoto, Azusa
    Matsumoto, Shingo
    Nishiyama, Akihiro
    Fukuda, Koji
    Takeuchi, Shinji
    Goto, Koichi
    Yano, Seiji
    CANCER SCIENCE, 2021, 112 : 764 - 764
  • [7] Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
    Ji, Jingran
    Mitra, Anupam
    Camidge, D. Ross
    Riess, Jonathan W.
    CLINICAL LUNG CANCER, 2021, 22 (06) : E851 - E855
  • [8] Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
    Tanimoto, Azusa
    Matsumoto, Shingo
    Takeuchi, Shinji
    Arai, Sachiko
    Fukuda, Koji
    Nishiyama, Akihiro
    Yoh, Kiyotaka
    Ikeda, Takaya
    Furuya, Naoki
    Nishino, Kazumi
    Ohe, Yuichiro
    Goto, Koichi
    Yano, Seiji
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1410 - 1420
  • [9] Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated With ALK-TKI sequences
    Tabbo, Fabrizio
    Muscarella, Lucia Anna
    Gobbini, Elisa
    Trombetta, Domenico
    Castellana, Stefano
    Rigutto, Angelica
    Galetta, Domenico
    Maiello, Evaristo
    Martelli, Olga
    Tiseo, Marcello
    Scotti, Vieri
    Ghilardi, Laura
    Gregorc, Vanesa
    Sergi, Concetta
    Pilotto, Sara
    Del Conte, Alessandro
    Cappuzzo, Federico
    Cortinovis, Diego
    Osman, Giorgia
    Bareggi, Claudia
    Di Maio, Massimo
    Rossi, Antonio
    Rossi, Giulio
    Bria, Emilio
    Volante, Marco
    Scagliotti, Giorgio Vittorio
    Graziano, Paolo
    Novello, Silvia
    Righi, Luisella
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 200 - 211
  • [10] The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK plus ) advanced NSCLC previously treated with crizotinib
    Carlson, Josh John
    Wong, William Bruce
    Canestaro, William
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345